Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly Collaboration Agreement[14] - Net loss for Q3 2025 was $15.8 million, compared to a net loss of $19.1 million in Q3 2024, reflecting improved financial performance[18] - Total operating expenses for Q3 2025 were $26.7 million, down from $31.7 million in Q3 2024[22] - General and administrative expenses were $6.7 million for Q3 2025, down from $7.0 million in Q3 2024, primarily due to lower facilities and IT-related expenses[18] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in FHD-286 and personnel-related expenses[14] - As of September 30, 2025, the company had $180.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028[18] Research and Development - FHD-909 is in a Phase 1 dose escalation trial targeting SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary focus[1] - The Selective CBP degrader program is advancing towards IND readiness in 2026, with promising preclinical data for ER+ breast cancer[7] - The Selective ARID1B degrader program is progressing towards in vivo proof-of-concept in 2026, targeting up to 5% of solid tumors[9] Collaboration - The company is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program[4]

Core Insights - Foghorn Therapeutics is advancing its clinical programs, particularly FHD-909, a first-in-class oral SMARCA2 selective inhibitor, in a Phase 1 trial targeting SMARCA4-mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][3] - The company is developing several selective degrader programs, including Selective CBP, EP300, and ARID1B degraders, with promising preclinical data indicating robust anti-tumor activity and favorable tolerability [2][6][7][8] - Foghorn has a strong financial position with $180.3 million in cash and equivalents as of September 30, 2025, providing a cash runway into 2028 [1][19] FHD-909 Program - FHD-909 is designed to selectively inhibit SMARCA2, showing significant anti-tumor activity in preclinical models of SMARCA4-mutant lung tumors [3][14] - The ongoing Phase 1 trial is progressing well, with enrollment on track and preclinical data supporting its combination with standard therapies [4][2] Selective Degrader Programs - The Selective CBP degrader is entering non-GLP toxicology studies with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [1][12] - The Selective EP300 degrader is showing broad efficacy across hematological malignancies, with IND-enabling studies expected in 2026 [1][7][12] - The Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026, targeting ARID1A-mutated cancers, which represent up to 5% of solid tumors [1][8][13] Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly collaboration [19] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in various areas [19] - The net loss for Q3 2025 was $15.8 million, an improvement from a net loss of $19.1 million in the same quarter of the previous year [19][22] Leadership Update - The Chief Financial Officer, Kristian Humer, will be leaving the company, with a search for a successor already underway [10]

Core Viewpoint - The conference call focuses on Foghorn's proprietary programs, particularly the selective ARID1B degrader, along with updates on other programs like selective CBP and EP300 degraders [2][4]. Group 1: Company Overview - Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs, leads the call and emphasizes the focus on Foghorn's selective ARID1B degrader and other proprietary programs [2]. - Adrian Gottschalk, President and CEO, will provide an overview of the company's recent progress [4]. Group 2: Pipeline Updates - The call will include updates on the progress of Foghorn's proprietary pipeline programs, specifically ARID1B, CBP, and EP300, along with new data presented [4].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Foghorn Therapeutics FY Conference Call Summary Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Date of Call**: October 30, 2025 - **Focus**: Updates on proprietary programs including selective ARID1B, CBP, and EP300 degraders [1][2][3] Key Industry Insights - **Chromatin Regulatory System**: Foghorn Therapeutics targets the chromatin regulatory system, which is implicated in cancer, with mutations found in up to 50% of tumors [4][5] - **Market Opportunity**: Successful drugs targeting this biology represent multi-billion-dollar opportunities [5] Core Programs and Developments 1. **FHD-909** - **Description**: First-in-class selective oral small molecule inhibitor of SMARCA2, targeting tumors with SMARCA4 mutations [7] - **Clinical Trial**: Currently enrolling patients in a phase 1 dose escalation trial in the US and Japan, focusing on non-small cell lung cancer patients with SMARCA4 mutations [8] - **Timeline**: Anticipated decision on dose expansion by Lilly in the first half of 2026 [8] 2. **Selective ARID1B Degrader** - **Significance**: First to publicly demonstrate robust degradation of ARID1B, targeting a population with ARID1A mutations found in approximately 5% of solid tumors [9][10] - **Clinical Context**: ARID1A mutations accelerate tumor genesis and promote metastases, indicating a high unmet medical need [17] - **Progress**: Achieved 80% degradation in preclinical models, with in vivo proof of concept expected in 2026 [19][20] 3. **Selective CBP Degrader** - **Target Population**: Potential in EP300 mutated cancers and ER-positive breast cancer, with over 200,000 cases diagnosed annually in the US [24][25] - **Mechanism**: Selective degradation of CBP could provide a wider therapeutic window than dual CBP/EP300 inhibitors, avoiding hematological toxicities [24][27] - **Development Status**: Pre-development candidate CBP degrader (CPPD171) is on track for IND readiness in 2026 [10][28] 4. **Selective EP300 Degrader** - **Target Indications**: Significant potential in hematological malignancies, particularly multiple myeloma, with approximately 100,000 patients in the US potentially benefiting [31][32] - **Clinical Validation**: Previous dual CBP/EP300 inhibitors have shown compelling results in multiple myeloma, supporting the approach [34] - **Development Timeline**: Tracking towards IND-enabling studies in 2026 [38] Additional Insights - **Mechanistic Understanding**: Foghorn emphasizes a biology-first approach, focusing on novel biology and targets, with a deep mechanistic understanding of the chromatin regulatory system [5][6] - **Partnership Strategy**: The company is considering partnerships for larger tumor types, particularly in breast cancer and multiple myeloma, to leverage resources for clinical studies [80][81] - **Feedback from Conferences**: Positive feedback received on the selective degradation of ARID1B, indicating significant interest and curiosity from industry peers [83] Conclusion Foghorn Therapeutics is advancing a robust pipeline of selective degraders targeting critical components of the chromatin regulatory system, with significant potential to address unmet medical needs in various cancers. The company is on track for key milestones in 2026, including IND readiness for multiple programs.

Core Insights - Foghorn Therapeutics Inc. is advancing its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, showcasing significant progress in addressing challenging cancer targets [1][2] Selective ARID1B Degrader Program - The Selective ARID1B degrader targets a dependency found in up to 5% of solid tumors, including endometrial, gastric, gastroesophageal junction, bladder, and non-small cell lung cancer [3][5] - The program is advancing towards in vivo proof of concept expected in 2026, with recent data presented at the TPD and Induced Proximity Summit [4][5] Selective CBP Degrader Program - The Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025, with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [5][8] - The program is designed to overcome challenges associated with dual inhibition of CBP and EP300, which have shown dose-limiting toxicities [7][9] Selective EP300 Degrader Program - The Selective EP300 degrader is focused on hematological malignancies such as multiple myeloma and diffuse large b-cell lymphoma, with IND-enabling studies planned for 2026 [9][10] - This program demonstrates encouraging anti-tumor efficacy and favorable tolerability in preclinical studies, differentiating itself from dual CBP/EP300 approaches [5][10] Company Overview - Foghorn Therapeutics is developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system, utilizing its Gene Traffic Control platform [11]

Core Insights - Foghorn Therapeutics is hosting a virtual investor event on October 30, 2025, to discuss updates on its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs [1][3] - The company will present significant progress on its Selective ARID1B degrader program at the TPD and Induced Proximity Summit, highlighting its potential for treating endometrial, gastric, and bladder cancers [2] Company Overview - Foghorn Therapeutics is focused on discovering and developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system [4] - The company utilizes its proprietary Gene Traffic Control platform to systematically study and validate potential drug targets within this system, with multiple product candidates in oncology [4] Event Details - The Keynote Plenary session will feature a presentation titled "Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins" on October 29, 2025 [3] - The virtual investor event will provide pipeline updates and will be accessible via the company's website after the conference [3]

Group 1 - Foghorn Therapeutics Inc. (FHTX) closed at $5.06, with a 1.4% gain over the past four weeks, and a mean price target of $11.67 suggests a 130.6% upside potential [1] - The average of six short-term price targets ranges from $9.00 to $14.00, indicating a potential increase of 77.9% to 176.7%, with a standard deviation of $2.25 reflecting the variability of estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 8% [4][12] Group 2 - FHTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets may not be reliable indicators of actual stock price movements, the direction implied by these targets can serve as a useful guide for further research [14]

Core Viewpoint - Foghorn Therapeutics Inc. (FHTX) has experienced a recent decline in share price, but the formation of a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings estimate revisions from analysts [1][2][7]. Group 1: Technical Analysis - The hammer chart pattern indicates that the stock may have found support, with bulls potentially counteracting the bears, signaling a possible trend reversal [1][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, suggesting that selling pressure may be exhausting [4][5]. - The effectiveness of the hammer pattern as a bullish indicator is enhanced when used alongside other bullish indicators [6]. Group 2: Fundamental Analysis - There has been a positive trend in earnings estimate revisions for FHTX, with the consensus EPS estimate increasing by 8% over the last 30 days, indicating analysts' optimism about the company's future earnings [7][8]. - FHTX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are improving, further supporting the potential for a turnaround in share price [10].

Company Performance - Foghorn Therapeutics Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.31, and an improvement from a loss of $0.45 per share a year ago, representing an earnings surprise of +9.68% [1] - The company posted revenues of $7.56 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.85%, but showing an increase from year-ago revenues of $6.89 million [2] - Over the last four quarters, Foghorn Therapeutics has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Market Outlook - Foghorn Therapeutics shares have increased by approximately 8.9% since the beginning of the year, outperforming the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.31 on revenues of $7.93 million, and for the current fiscal year, it is -$1.27 on revenues of $29.82 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Foghorn Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]